Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback